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signiﬁcantly increases the risk of hepatocellular carcinoma (HCC).
In contrast, not only obesity but also underweight is associated
with poor prognosis in patients with HCC. Differences in body
composition rather than BMI were suggested to be true determi-
nants of prognosis. However, this hypothesis has not been dem-
onstrated conclusively.
Methods:We measured skeletal muscle index (SMI), mean mus-
cle attenuation (MA), visceral adipose tissue index, subcutaneous
adipose tissue index, and visceral to subcutaneous adipose tissue
area ratios (VSR) via computed tomography in a large-scale retro-
spective cohort of 1257 patients with different stages of HCC, and
comprehensively analyzed the impact of body composition on
the prognoses.
Results: Among ﬁve body composition components, low SMI
(called sarcopenia), low MA (called intramuscular fat [IMF] depo-
sition), and high VSR (called visceral adiposity) were signiﬁcantly
associated with mortality, independently of cancer stage or
Child-Pugh class. A multivariate analysis revealed that sarcopenia
(hazard ratio [HR], 1.52; 95% conﬁdence interval [CI], 1.18–1.96;
p = 0.001), IMF deposition (HR, 1.34; 95% CI, 1.05–1.71;
p = 0.020), and visceral adiposity (HR, 1.35; 95% CI, 1.09–1.66;
p = 0.005) but not BMI were signiﬁcant predictors of survival.Journal of Hepatology 20
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Conclusions: Sarcopenia, IMF deposition, and visceral adiposity
independently predict mortality in patients with HCC. Body com-
position rather than BMI is a major determinant of prognosis in
patients with HCC.
 2015 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth most frequently diag-
nosed cancer and the third most frequent cause of cancer-related
death [1]. Recent epidemiological studies have resulted in the
wide recognition of obesity as a signiﬁcant risk factor for HCC
development [2]. We found previously that underweight patients
with a BMI <18.5 kg/m2 have the lowest risk among patients with
chronic hepatitis C [3]. However, we recently conducted a nation-
wide survey to explore the association between BMI and mortal-
ity in patients with non-viral HCC, and unexpectedly identiﬁed
not only obesity but also underweight status as a risk factor pre-
dicting poor survival [4]. Such a paradoxical relationship of
underweight (high mortality despite low susceptibility) has also
been found in patients with coronary heart disease [5], diabetes
[6], and renal cell carcinoma [7], and our study was the ﬁrst to
show in patients with HCC. One possible explanation for such a
relationship is that underweight patient groups may include
those with more advanced disease. However, the observed trend
remained after adjusting for signiﬁcant factors, such as tumor
stage and liver functional status, indicating that underweight
patients exhibit other key features associated with a poor
prognosis.
BMI is a simple anthropometric index based on individual
weight and height and is widely used. However, such simplicity15 vol. 63 j 131–140
Fig. 1. Cross-sectional computed tomography (CT) images of the third lumbar
vertebra used to quantify body composition variables. (A1–2) illustrates the
ﬁndings of two patients with hepatocellular carcinoma. The BMIs of the two
patients were almost identical. The red shadows, the green shadows, and the blue
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comes with a cost. BMI is limited anthropometrically, in that it
does not assess individual components of body weight such as
regional fat distribution or muscle volume. Regional fat distribu-
tion plays a crucial role in patients with metabolic syndrome [8].
In fact, we previously reported that visceral fat accumulation,
rather than BMI, is an independent risk factor for recurrence of
HCC in patients with non-viral disease [9]. Furthermore, loss of
skeletal muscle, called sarcopenia, is associated with poor prog-
noses of several cancers including HCC [10,11]. Sarcopenia may
be linked to a poor prognosis not only pathophysiologically by
inducing insulin resistance, but also indirectly, by reducing activ-
ities associated with daily living [12]. Based on such ﬁndings,
Ahima et al. proposed a new hypothesis that differences in body
composition rather than BMI may be true determinants of prog-
nosis [13]. However, most previous studies investigated only the
impacts of single body composition components on prognosis
[14]; thus, this hypothesis has not been proven conclusively.
In the present study, we explored BMI, skeletal muscle area,
intramuscular fat (IMF) deposition, abdominal adipose tissue area
and adipose tissue distribution in a large-scale retrospective
cohort of 1257 patients with different stages of HCC and compre-
hensively analyzed the impact of body composition on the prog-
noses of such patients.shadows show the skeletal muscle areas, the visceral adipose tissue areas, and the
subcutaneous adipose tissue areas, respectively. B1–3 illustrates the skeletal
muscle area in the three patients, which were nearly identical. The yellow
shadows indicate muscle attenuation from 29 to 29 HU. BMI, body mass index;
SMI, skeletal muscle index; SATI, subcutaneous adipose tissue index; VATI,
visceral adipose tissue index; VSR, visceral to subcutaneous adipose tissue area
ratio; MA, muscle attenuation; HU, Hounsﬁeld units.Patients and methods
This study was conducted according to ethical guidelines relevant to epidemio-
logical research promulgated by the Japanese Ministry of Education, Culture,
Sports, Science and Technology and the Ministry of Health, Labor, and Welfare.
The study design was described in a comprehensive protocol prepared by the
Department of Gastroenterology, the University of Tokyo Hospital and was
approved by the University of Tokyo Medical Research Center Ethics Committee
(approval number 2058).
Patients
Using a prospective computerized database, we analyzed information on patients
diagnosed with HCC at the Department of Gastroenterology, the University of
Tokyo Hospital, a tertiary center, from January 2004 to December 2009. We
excluded patients with poorly controlled ascites, because this might lead to over-
estimation of BMI. We included patients with undetected ascites due to diuretic
agent usage, since the exclusion of such patients might constitute selection bias.
HCC was diagnosed using unenhanced and dynamic computed tomography (CT)
[15]. Images were obtained during the early arterial, late arterial, and equilibrium
phases, thus at 28, 40, and 120 s after bolus injection of iodinated contrast mate-
rial. Images were reconstructed at a section thickness of 5 mm and with a recon-
struction interval of 5 mm (section thickness 2–2.5 mm, interval 1.5–2 mm, and
ﬁeld of view 24–35 cm for the arterial phase). A diagnosis of HCC was based on
typical CT ﬁndings: hyperattenuation in the arterial and hypoattenuation in the
equilibrium phase [16,17]. We assessed HCC stage using the Barcelona Clinic
Liver Cancer (BCLC) staging system [18].
Clinical and anthropometric variables
We recorded the following clinical and anthropometric parameters upon ﬁrst
admission to our department: age; gender; BMI; hepatitis infection status (hepa-
titis B virus [HBV], hepatitis C virus [HCV], HBV + HCV, or none); daily alcohol
consumption (680 g vs. >80 g); smoking status (never, former or current smoker);
presence of diabetes; presence of chronic kidney disease deﬁned by estimated
glomerular ﬁltration rate <60.0 ml/min/1.73 m2; history of cardiovascular or
cerebrovascular disease; history of lung disease such as asthma and chronic
obstructive pulmonary disease; Child-Pugh class; aspartate aminotransferase,
alanine transaminase, total bilirubin, and albumin levels; platelet count; BCLC
stage; treatment methods for patients with HCC in BCLC 0 or A; history of previ-
ous HCC treatment; and alpha-fetoprotein level (<100 vs. P100 ng/ml). We also
evaluated the body composition parameters described below. We considered132 Journal of Hepatology 201the deﬁnitions of underweight and obese typically applied to older adults [19]
and Japanese populations [20], and we selected the following BMI categories a
priori: <20.0, underweight; 20.0–24.9, normal; and P25.0, obese. Diabetes was
diagnosed based on medical history or a 75-g oral glucose tolerance test [21].
CT analyses of body composition variables
We quantiﬁed the data from a cross-sectional unenhanced CT image (Aquilion
4/16/64, ONE; Toshiba, Tokyo, Japan; LightSpeed Qx/I, LightSpeed Ultra,
LightSpeed VCT, Discovery CT 750 HD; GE Healthcare, Milwaukee, WI, USA) taken
solely for the purpose of diagnosing and staging HCC, as described below. We
evaluated CT scans performed within 1 month before, or soon after, the ﬁrst
admission to our department. The following measurements were validated by
the anatomical radiologists.
We analyzed the cross-sectional CT images at the third lumbar vertebra (L3)
using Slice-O-Matic software (version 5.0; Tomovision, Montreal, Canada) to
determine skeletal muscle and abdominal adipose tissue area. Muscle areas
included the psoas, erector spinae, quadratus lumborum, transversus abdominis,
external and internal obliques, and rectus abdominis muscles. Tissue Hounsﬁeld
unit (HU) thresholds were employed as follows: 29 to 150 HU for skeletal mus-
cle, 190 to 30 for subcutaneous adipose tissue and 150 to 50 for visceral
adipose tissue [22]. As in previous reports, these body composition variables were
normalized for height in meters squared and are expressed as cm2/m2. We
termed the parameters for skeletal muscle, subcutaneous and visceral adipose tis-
sue as skeletal muscle index (SMI), subcutaneous adipose tissue index (SATI), and
visceral adipose tissue index (VATI), respectively. We also calculated visceral to
subcutaneous adipose tissue area ratios (VSRs) to explore abdominal adipose tis-
sue distributions. In addition, we calculated mean MA using the same CT images
to assess skeletal muscle quality. Low MA indicates increased IMF content that
contributes to muscle weakness independent of the age-associated loss in muscle
mass [10,23]. Representative images used for analyses are shown in Fig. 1.
We evaluated reproducibility by analyzing data from 70 subjects randomly
selected from this cohort to test the reliability of body composition determined
by CT. Two trained observers (N.F. and R.N.) measured skeletal muscle area, the
corresponding muscle mean CT attenuation, and subcutaneous and visceral adi-
pose tissue area to assess inter-observer reproducibility. One observer repeated
the measurements at two time points at least 1 month apart to assess
intra-observer reproducibility.5 vol. 63 j 131–140
Table 1. Baseline characteristics.
Characteristic N = 1,257
Age, mean ± SD 68.8 ± 9.2
Gender male, N (%) 828 (65.9)
Body mass index (kg/m2), median (IQR) 23.2 (21.2-25.5)
<20.0 (underweight), N (%) 186 (14.8)
20.0-24.9 (normal weight), N (%) 700 (55.7)
≥25.0 (obesity), N (%) 371 (29.5)
Viral status, N (%)
HCV/HBV/HCV + HBV/none 895/142/13/207 (71.2/11.3/1.0/16.5)
Alcohol consumption, N (%)
>80 g per day 191 (15.2)
Smoking status, N (%)*
Never/former/current 645/328/239 (53.2/27.1/19.7)
Comorbidity, N (%)
Diabetes† (yes/no) 310/848 (26.8/73.2)
Cardio/cerebrovascular disease‡ (yes/no) 142/1080 (11.6/88.4)
Pulmonary disease‡ (yes/no) 46/1176 (3.8/96.2)
Chronic kidney disease§ (yes/no) 281/973 (22.4/77.6)
Child-Pugh class, N (%)
A/B/C 958/286/13 (76.2/22.8/1.0)
AST (IU/L), median (IQR) 53 (36-74)
ALT (IU/L), median (IQR) 44 (28-69)
Total bilirubin (mg/dl), median (IQR) 0.8 (0.6-1.1)
Albumin (g/dl), median (IQR) 3.7 (3.3-4.0)
Prothrombin time (%), median (IQR) 83 (71-99)
Platelet count (× 1000/μl) , median (IQR) 110 (79-152)
BCLC stage, N (%)
0/A/B/C/D 181/588/427/47/14 (14.4/46.8/34.0/3.7/1.1)
Previous treatment (yes/no), N (%) 471/786 (37.5/62.5)
α-fetoprotein (<100/≥100 ng/ml) , N (%) 979/278 (77.9/22.1)
Body composition variable
SMI (cm2/m2), median (IQR) 42.4 (36.6-48.7)
Male/female I 45.8 (40.3-50.9)/36.7 (32.9-40.7)
MA (HU), median (IQR) 35.2 (29.8-40.9)
Male/female 38.0 (32.7-42.8)/30.9 (25.8-35.5)
VATI (cm2/m2), median (IQR) 31.8 (17.4-51.9)
Male/female 36.4 (20.3-56.3)/25.5 (13.9-40.5)
SATI (cm2/m2), median (IQR) 41.1 (29.7-56.4)
Male/female 37.7 (27.0-50.0)/51.1 (34.4-72.5)
VSR, median (IQR) 0.75 (0.46-1.11)
Male/female 0.93 (0.64-1.28)/0.49 (0.33-0.66)
I
II
II
II
II
SD, standard deviation; IQR, interquartile range; HCV, hepatitis s C virus; HBV hepatitis B virus; AST, aspartate aminotransferase; ALT, alanine transaminase; BCLC,
Barcelona Clinic Liver Cancer; SMI, skeletal muscle index; VATI, visceral adipose tissue index; SATI, subcutaneous adipose tissue index; VSR, visceral to subcutaneous fat
area ratio; MA, muscle attenuation.
*Data of 45 patients were missing.
Data of 99 patients were missing.
Data of 35 patients were missing.
§Data of three patients were missing.
kSigniﬁcant differences were observed in each of the body composition variables between males and females.
JOURNAL OF HEPATOLOGYStatistical analyses
Quantitative variables are expressed as medians with interquartile ranges, unless
otherwise indicated. Numbers and percentages are used to express the qualitative
variables. Differences between groups were analyzed using Wilcoxon’s test for
continuous variables and Pearson’s v2 test or Fisher’s exact test for categorical
data. A survival analysis was performed on a per-patient basis. Survival time
was deﬁned as the interval between the ﬁrst admission to our department for
HCC and death or December 31, 2012, whichever came ﬁrst. Cumulative mortality
curves were constructed using the Kaplan–Meier procedure and compared with
log-rank test results. In addition, we explored liver-related mortality, which
included death caused directly by HCC progression, including rupture of tumors
or gastroesophageal varices due to HCC invasion of the portal vein; advancedJournal of Hepatology 201hepatic failure (massive ascites, jaundice, or overt hepatic encephalopathy); or
bleeding varices. We censored liver-unrelated death at the time of the cumulative
liver-related mortality evaluation. We also assessed differences in cumulative
recurrence rates in patients with HCC in BCLC stage 0 or A, who had undergone
percutaneous therapy as the ﬁrst treatment between those with or without unfa-
vorable body composition.
Univariate and multivariate analyses of overall survival were performed
using Cox’s regression models, and the results are presented as HRs with 95%
CIs. p values were derived using the Wald test. Variables exhibiting signiﬁcant
associations after univariate analyses were included in the multivariate analysis.
First, we assessed the HRs of SMI, MA, VATI, SATI, and VSR for mortality as
continuous numbers using the restricted cubic spline with three knots at the
5th, 50th, and 95th centiles after adjusting for gender [24]. Then, we determined5 vol. 63 j 131–140 133
100
80
60
40
20
0
0 1 2 3 4 5
Log-rank p <0.001
M
or
ta
lit
y 
(%
)
Low SMI (sarcopenia)
High SMI (non-sarcopenia)
All-cause mortality
YearPatients at risk
Non-sarcopenia
Sarcopenia 139 118 101 74 52 23
1118 1019 892 775 555 363
100
80
60
40
20
0
0 1 2 3 4 5
Log-rank p <0.001
M
or
ta
lit
y 
(%
)
Liver-related mortality
Year
139 118 101 74 52 23
1118 1019 892 775 555 363
Patients at risk
Patients at risk
100
80
60
40
20
0
0 1 2 3 4 5
Log-rank p <0.001
M
or
ta
lit
y 
(%
)
100
80
60
40
20
0
0 1 2 3 4 5
Log-rank p = 0.006
M
or
ta
lit
y 
(%
)
100
80
60
40
20
0
0 1 2 3 4 5
Log-rank p <0.001
M
or
ta
lit
y 
(%
)
100
80
60
40
20
0
0 1 2 3 4 5
Log-rank p = 0.001
M
or
ta
lit
y 
(%
)
IMF deposition
Non-IMF deposition
Visceral adiposity
Non-visceral adiposity
High VSR (visceral adiposity)
Low VSR (non-visceral adiposity)
Low MA (IMF desposition)
High MA (non-IMF deposition)
Year Year
Year Year
1069 965 835 707 495 295
188 172 158 142 112 91
1069 965 835 707 495 295
188 172 158 142 112 91
229 200 168 136 93 60
1028 937 825 713 514 326
229 200 168 136 93 60
1028 937 825 713 514 326
A
B
C
D
E
F
Fig. 2. Overall survival curves according to body composition variables. (A–C)
All-cause mortality curves in patients with or without each body composition
component. (D–F) Liver-related mortality curves in patients with or without each
body composition component. SMI, skeletal muscle index; MA, muscle attenu-
ation; IMF, intramuscular fat; VSR, visceral to subcutaneous adipose tissue area
ratio.
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Fig. 3. Deﬁnitions of sarcopenia, intramuscular fat deposition and visceral
adiposity and associations between body composition components. (A)
Deﬁnitions of the prognostic body composition components. (B–D) The correla-
tions between SMI, MA, and VSR were weak, although statistically signiﬁcant. (E)
Mortality risk increased based on the increase in the number of prognostic body
composition components, suggesting that they were complementary predictors
for a poor prognosis in patients with hepatocellular carcinoma. SMI, skeletal
muscle index; MA, muscle attenuation; IMF, intramuscular fat; VSR, visceral to
subcutaneous adipose tissue area ratio.
Research Articleoptimal cut-off values for the body composition variables used to predict mortal-
ity, with the aid of maximally selected rank statistics, as described by Lausen [25].
Such cut-off values optimally separate patients into good and poor prognosis
groups. Statistically signiﬁcant differences in prognoses derived using these
cut-off values were examined after adjusting the p values, reﬂecting the fact that
multiple testing was in play. As body composition varies by ethnicity and patient
population, we re-estimated the optimal cut-off values of variables in our study
cohort. We assessed the inﬂuences of body composition variables on survival
using these new values.
Propensity scoring was used to control of selection bias and potential con-
founding [26]. The propensity scores for those with and without each prognostic
body composition were evaluated non-parametrically using the following vari-
ables [27]: age; gender; viral status; BCLC stage; treatment methods for BCLC
stage 0/A; prothrombin time; presence of previous treatment; and presence of
chronic kidney disease. Propensity score-matching was performed with a caliper
width of 0.1 multiplied by the standard deviation for the linearly transformed
propensity scores. After amending these confounding factors, the all-cause and
liver-related mortality analysis was repeated.
We also evaluated the associations between BMI and elements of body com-
position. Furthermore, we investigated the inﬂuences of BMI and body composi-
tion components on survival.134 Journal of Hepatology 201Statistical analyses were performed using R software (version 3.1.2; http://
www.R-project.org) using the ‘‘survival’’, ‘‘maxstat’’, ‘‘rms’’ and ‘‘MatchIt’’ pack-
ages. All tests were two-sided, and a p value <0.05 was considered signiﬁcant.Results
Patient characteristics
Of the 1490 consecutive patients with HCC admitted to our
department between January 2004 and December 2009, 188
(12.6%) were excluded because they lacked CT imaging data
and/or notes on anthropometric parameters. We excluded 45
patients with uncontrolled ascites (3.0%). Accordingly, we
assessed 1257 patients (84.4%) retrospectively.
Mean patient age was 68.8 ± 9.2 years, and HCV infection was
most prevalent in this cohort (71.2%). The BCLC stage distribution
was as follows: stage 0, 181 (14.4%); stage A, 588 (46.8%); stage B,5 vol. 63 j 131–140
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427 (34.0%); stage C, 47 (3.7%); and stage D, 14 patients (1.1%).
Other baseline characteristics are shown in Table 1. The treat-
ment methods for the 769 patients with HCC in BCLC stage 0/A
were shown in Supplementary Table 1.
First, we analyzed the impact of BMI on mortality. Consistent
with the data of a nationwide survey of patients with non-viral
HCC [4], both obesity (BMI >25 kg/m2) and underweight status
(BMI <20 kg/m2) were associated with higher mortality in our
cohort, composed principally of patients with HCV-related HCC.
This result suggests that the U-shaped relationship between
BMI and mortality is common, regardless of underlying liver dis-
ease (Supplementary Fig. 1).Table 2. Clinicopathological characteristics in the patients with sarcopenia, intramu
Sarcopenia
Yes
(N = 139)
No
(N = 1118) 
p value Yes
(N = 1
Age, mean ± SD 73.9 ± 7.3 68.1 ± 9.2 <0.001 69.8 ±
Gender, N (%) 0.45
Male 96 (69.1) 732 (65.5) 690 (6
Female 43 (30.9) 386 (34.5) 379 (3
Body mass index (kg/m2), 
median (IQR)
19.7 (17.9-21.9) 23.6 (21.7-
25.7)
<0.001 23.3 (
Viral status, N (%) <0.001
HCV 119 (85.6) 776 (69.4) 772 (7
HBV 4 (2.9) 138 (12.3) 99 (9.
HCV + HBV 0 (0) 13 (1.2) 10 (0.
None 16 (11.5) 191 (17.1) 188 (1
Alcohol consumption, N (%) 0.25
>80 g per day 16 (11.5) 175 (15.7) 164 (1
Smoking status, N (%)* 0.47
Never 72 (53.3) 573 (53.2) 545 (5
Former 41 (30.4) 287 (26.6) 287 (2
Current 22 (16.3) 217 (20.2) 204 (1
Comorbidity, N (%)
Diabetes† (yes/no) 24/101 
(19.2/80.8)
286/747 
(27.7/72.3)
0.08 270/7
(27.4/
Cardio/cerebrovascular 
disease‡ (yes/no)
20/116 
(14.7/85.3)
122/964 
(11.2/88.8)
0.29 126/9
(12.1/
Pulmonary disease‡ 
(yes/no)
9/127 (6.6/93.4) 37/1,049 
(3.4/96.6)
0.09 38/1,0
(3.6/9
Chronic kidney disease§ 
(yes/no)
37/102 
(26.6/73.4)
244/871 
(21.9/78.1)
0.25 250/8
(23.4/
Child-Pugh class, N (%) 0.57
A 109 (78.4) 849 (75.9) 820 (7
B 28 (20.2) 258 (23.1) 237 (2
C 2 (1.4) 11 (1.0) 12 (1.
AST (IU/L), median (IQR) 55 (38-74) 52 (36-74) 0.53 52 (36
ALT (IU/L), median (IQR) 44 (26-61) 44 (28-70) 0.25 43 (28
Total bilirubin (mg/dl), 
median (IQR)
0.8 (0.6-1.1) 0.8 (0.6-1.1) 0.12 0.8 (0
Albumin (g/dl), median (IQR) 3.7 (3.3-3.9) 3.7 (3.4-4.0) 0.47 3.7 (3
Prothrombin time (%), 
median (IQR)
91 (75-100) 82 (71-97) <0.001 84 (72
Journal of Hepatology 201Association between body composition and mortality in patients
with hepatocellular carcinoma
Next, we analyzed ﬁve indicators of body composition, SMI, MA,
VATI, SATI and VSR, in this cohort using CT scans taken at the ﬁrst
admission to our department. Measurements of these indicators
were consistent and highly reproducible among observers
(Supplementary Fig. 2). SATI was strongly correlated, and SMI
and VATI were moderately correlated with BMI (Supplementary
Fig. 3). However, MA and VSR had only weak correlations with
BMI, indicating that BMI cannot be used to accurately assess indi-
vidual body composition components. In fact, two patientsscular fat deposition and visceral adiposity.
Intramuscular fat deposition Visceral adiposity
069)
No
(N = 188)
p value Yes
(N = 229)
No
(N = 1028)
p value
 8.7 62.8 ± 9.9 <0.001 70.5 ± 7.9 68.4 ± 9.4 <0.001
0.022 <0.001
4.5) 138 (73.4) 186 (81.2) 642 (62.5)
5.5) 50 (26.6) 43 (18.8) 386 (37.5)
21.3-25.6) 22.6 (20.7-
25.0)
0.018 24.4 (22.3-
26.6)
23.0 (20.9-
25.2)
<0.001
<0.001 <0.001
2.2) 123 (65.4) 125 (54.6) 770 (74.9)
3) 43 (22.9) 19 (8.3) 123 (12.0)
9) 3 (1.6) 2 (0.9) 11 (1.0)
7.6) 19 (10.1) 83 (36.2) 124 (12.1)
0.81 0.048
5.3) 27 (14.4) 45 (19.7) 146 (14.2)
0.45 0.003
2.6) 100 (56.8) 94 (42.7) 551 (55.5)
7.7) 41 (23.3) 74 (33.6) 254 (25.6)
9.7) 35 (19.9) 52 (23.6) 187 (18.9)
17 
72.6)
40/131 
(23.4/76.6)
0.32 83/128 
(39.3/60.7)
227/720 
(24.0/76.0)
<0.001
18 
87.9)
16/162 
(9.0/91.0)
0.29 29/193 
(13.1/86.9)
113/887 
(11.3/88.7)
0.53
06 
6.4)
8/170 
(4.5/95.5)
0.73 7/215 
(3.2/96.8)
39/961 
(3.9/96.1)
0.74
17 
76.6)
31/156 
(16.6/83.4)
0.048 73/155 
(32.0/68.0)
208/818 
(20.3/79.7)
<0.001
0.46 0.13
6.7) 138 (73.4) 186 (81.2) 772 (75.1)
2.2) 49 (26.1) 42 (18.3) 244 (23.7)
1) 1 (0.5) 1 (0.5) 12 (1.2)
-74) 53 (38-70) 0.69 47 (31-69) 54 (38-74) <0.001
-69) 49 (29-69) 0.10 38 (25-64) 44 (29-69) 0.027
.6-1.1) 0. 9(0.6-1.2) 0.28 0.8 (0.6-
1.1)
0.8 (0.6-
1.1)
0.029
.3-4.0) 3.7 (3.4-4.0) 0.29 3.8 (3.5-
4.1)
3.7 (3.3-
4.0)
0.004
-100) 77 (67-86) <0.001 86 (75-100) 82 (71-98) 0.004
(continued on next page)
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Table 2 (continued)
Sarcopenia Intramuscular fat deposition Visceral adiposity
Yes
(N = 139)
No
(N= 1118) 
p value Yes
(N = 1069)
No
(N= 188)
p value Yes
(N = 229)
No
(N = 1028)
p value
Platelet count (× 1000/μl), 
median (IQR)
116 (87-159) 111 (78-150) 0.09 110 (79-153) 114 (76-144) 0.43 126 (93-175) 107 (77-146) <0.001
BCLC stage, N (%) 0.41 0.71 0.076
0 16 (11.5) 165 (14.8) 156 (14.6) 25 (13.3) 31 (13.5) 150 (14.6)
A 63 (45.3) 525 (47.0) 495 (46.3) 93 (49.5) 94 (41.0) 494 (48.1)
B 50 (36.0) 377 (33.7) 364 (34.1) 63 (33.5) 89 (38.9) 338 (32.9)
C 8 (5.8) 39 (3.5) 41 (3.8) 6 (3.2) 13 (5.7) 34 (3.3)
D 2 (1.4) 12 (1.1) 13 (1.2) 1 (0.5) 2 (0.9) 12 (1.2)
Previous treatment, N (%) 0.31 0.51 0.005
Yes/no 58/81 
(41.7/58.3)
413/705 
(36.9/63.1)
396/673 
(37.0/63.0)
75/113 
(39.9/60.1)
105/124 
(45.9/54.1)
366/662 
(35.6/64.4)
α-fetoprotein, N (%) 0.14 0.35 0.28
<100 ng/ml/≥100 ng/ml 101/38 
(72.7/27.3)
878/240 
(78.5/21.5)
838/231 
(78.4/21.6)
141/47 
(75.0/25.0)
185/44 
(80.8/19.2)
794/234 
(77.2/22.8)
SD, standard deviation; IQR, interquartile range; HCV, hepatitis s C virus; HBV hepatitis B virus; AST, aspartate aminotransferase; ALT, alanine transaminase; BCLC,
Barcelona Clinic Liver Cancer.
*Data of 45 patients were missing.
Data of 99 patients were missing.
Data of 35 patients were missing.
§Data of three patients were missing.
Research Articleshown in Fig. 1A1 and A2 had a similar BMI, whereas their body
components were quite different. Moreover, as shown in
Fig. 1B1–3, the areas of lower muscle attenuation were different
among three patients despite a similar SMI.
We assessed the impacts of these indicators on all-cause
mortality as a continuous variable using the restricted cubic
spline estimation (Supplementary Fig. 4). SMI (p = 0.009) and
MA (p = 0.024) were signiﬁcant factors for mortality, and
higher VSR had a tendency towards poor prognosis
(p = 0.11). In contrast, VATI and SATI were not associated with
mortality. Therefore, we focused on SMI, MA, and VSR in this
study.
We performed exploratory analyses to establish the optimal
cut-off values of SMI, MA, and VSR to distinguish patients with
poor prognostic body composition. As signiﬁcant gender differ-
ences in those variables were evident (Table 1), cut-off values
were calculated by gender. Although those were also correlated
with age, we did not set different cut-off values by age to inves-
tigate whether functional age or chronological age was more
important for the prognosis of patients with HCC. Actually,
Hubbard et al. proposed that sarcopenia determined by CT
might be a functional age biomarker [28]. Using the maximally
selected rank statistics, the cut-off values for SMI were
36.2 cm2/m2 in male and 29.6 cm2/m2 in female, those for MA
were 44.4 HU in male and 39.3 HU in female, and those for
VSR were 1.33 in male and 0.93 in female, respectively. To con-
ﬁrm the validities of these cut-off values, we analyzed the sur-
vival rates of groups stratiﬁed by each cut-off point using a
Kaplan–Meier analysis. As shown in Fig. 2, patients with low
SMI (n = 139, 11.1%), low MA (n = 1069, 85.0%) and high VSR
(n = 229, 18.2%) showed signiﬁcantly higher all-cause mortality
rates than those of the others (Fig. 2A–C). In addition, patients
with low SMI, low MA and high VSR also exhibited higher
liver-related mortality rates (Fig. 2D–F), suggesting that these136 Journal of Hepatology 201body composition factors may be associated with the progres-
sion of liver disease.
To render these descriptors intelligible, we termed low SMI,
low MA, and high VSR as sarcopenia, IMF deposition, and visceral
adiposity, respectively (Fig. 3A). Scatterplots between SMI, MA,
and VSR revealed weak relationships, although they were statis-
tically signiﬁcant (Fig. 3B–D). In addition, these three factors con-
tributed to increase mortality risk in an additive manner (Fig. 3E),
suggesting that they are complementary predictors for a poor
prognosis in patients with HCC.
The clinicopathological characteristics of the patients with
and without sarcopenia, IMF deposition, and visceral adiposity
are shown in Table 2. Patients with sarcopenia, IMF deposition,
and visceral adiposity were signiﬁcantly older than those with-
out. BMI was signiﬁcantly lower in patients with sarcopenia,
and higher in patients with IMF deposition and visceral adiposity.
Current smoker, diabetes and chronic kidney disease were more
frequently seen in patients with visceral adiposity. Notably, none
of these three factors was signiﬁcantly associated with BCLC
stage or Child-Pugh class.Impacts of body composition on recurrence and mortality in patients
with very early/early stage HCC who underwent curative treatment
To further elucidate the potential effect of body composition on
HCC prognosis, we performed a subgroup analysis composed of
515 patients with very early/early stage HCC (BCLC stage 0/A)
who underwent curative treatment by percutaneous radiofre-
quency ablation as a ﬁrst treatment. As shown in
Supplementary Fig. 5, only sarcopenia was associated with a
higher risk for HCC recurrence (Supplementary Fig. 5D–F), but
all three factors were signiﬁcantly associated with higher mortal-
ity (Supplementary Fig. 5A–C).5 vol. 63 j 131–140
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Multivariate risk and propensity score-matching analyses
We performed a multivariate analysis to identify factors indepen-
dently associated with all-cause mortality (Table 3). Although
both underweight status and obesity were signiﬁcantly associ-
ated with higher mortality in the univariate analysis, they were
no longer signiﬁcant prognostic factors after the multivariate
analysis. In contrast, sarcopenia (HR, 1.52; 95% CI, 1.18–1.96;
p = 0.001), IMF deposition (HR, 1.34; 95% CI, 1.05–1.71;
p = 0.020), and visceral adiposity (HR, 1.35; 95% CI, 1.09–1.66;
p = 0.005) were independently associated with a poor prognosis.
Importantly, these body composition factors were more strongly
associated with a poor prognosis than older age (P70 years) (HR,
1.16; 95% CI, 0.97–1.38; p = 0.10). The propensity score-matching
analysis conﬁrmed that all three factors were associated with
all-cause and liver-related mortality (Supplementary Table 2
and Supplementary Fig. 6).Table 3. Univariate and multivariate analyses for all-cause mortality.
     5-year mortality
Variable No. at 
risk
No. 
of events
(%) (95% CI)
BMI
Underweight 186 96 57.4 (48.0-64.9)
Normal weight 700 328 42.8 (38.6-46.7)
Obesity 371 183 48.6 (42.5-54.1)
Sarcopenia
No 1118 518 44.0 (40.7-47.2)
Yes 139 89 67.4 (56.6-75.5)
IMF deposition
No 188 83 37.1 (29.3-44.1)
Yes 1069 524 48.2 (44.8-51.6)
Visceral adiposity
No 1028 478 54.5 (41.2-48.0)
Yes 229 129 44.7 (46.7-61.1)
Age
<70 years old 597 267 40.8 (36.3-45.0)
≥70 years old 660 340 52.0 (47.4-56.2)
Gender, n (%)
Male 828 407 47.3 (43.3-50.9)
Female 429 200 45.0 (39.5-50.0)
Viral status, n (%)
HBV 142 42 29.5 (20.9-37.2)
HCV 895 448 47.5 (43.7-51.1)
HCV + HBV 13 8 72.7 (16.5-91.1)
None 207 109 53.1 (44.5-60.3)
Alcohol consumption 
≤80 g per day 1066 508 45.6 (42.1-48.9)
>80 g per day 191 99 51.5 (43.0-58.8)
Smoking status*
Never 645 306 44.8 (40.4-48.9)
Former 328 145 46.5 (38.9-51.4)
Current 239 127 48.6 (41.1-55.1)
Diabetes†
No 848 411 45.8 (41.9-49.4)
Yes 310 145 45.1 (38.5-51.0)
Journal of Hepatology 201Impact of prognostic body composition on mortality according to
BMI
We divided the patients into three groups in terms of the number
of prognostic body composition factors; i.e., 0, 1 and 2, or 3, and
assessed the impact of body composition on all-cause mortality
according to BMI category. As shown in Fig. 4A, mortality risk
tended to increase in accordance with increasing number of prog-
nostic body composition components in all categories, and this
tendency was most apparent in underweight patients.
Furthermore, the proportion of patients who had two or three
poor prognostic body composition components was signiﬁcantly
higher in underweight and obese patients than that in normal
weight patients (Fig. 4B). This ﬁnding was consistent with the
U-shaped relationship between BMI and mortality shown in
Supplementary Fig. 1.Univariate Multivariate analysis
HR 95% CI p value HR 95% CI p value
1.35 (1.08-1.70) 0.010 1.08 (0.84-1.39) 0.55
1.00 (referent) 1.00 (referent)
1.22 (1.02-1.46) 0.032 1.00 (0.83-1.22) 0.97
1.00 (referent) 1.00 (referent)
1.83 (1.46-2.30) <0.001 1.52 (1.18-1.96) 0.001
1.00 (referent) 1.00 (referent)
1.52 (1.21-1.92) <0.001 1.34 (1.05-1.71) 0.020
1.00 (referent) 1.00 (referent)
1.46 (1.21-1.78) <0.001 1.35 (1.09-1.66) 0.005
1.00 (referent) 1.00 (referent)
1.36 (1.16-1.60) <0.001 1.16 (0.97-1.38) 0.10
1.00 (referent)
0.95 (0.81-1.13) 0.59
1.00 (referent) 1.00 (referent)
2.00 (1.46-2.75) <0.001 1.65 (1.18-2.31) 0.003
3.24 (1.52-6.91) 0.002 3.51 (1.63-7.57) 0.001
2.56 (1.79-3.66) <0.001 2.13 (1.46-3.10) <0.001
1.00 (referent)
1.14 (0.92-1.42) 0.22
1.00 (referent)
0.99 (0.81-1.21) 0.92
1.12 (0.92-1.38) 0.27
1.00 (referent)
1.08 (0.90-1.31) 0.41
(continued on next page)
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Table 3 (continued)
   5-year mortality Univariate Multivariate analysis
Variable No. at risk No.  
of events
(%) (95% CI) HR 95% CI p value HR 95% CI p value
Chronic kidney disease‡
No 973 459 44.3 (40.7-47.7) 1.00 (referent) 1.00 (referent)
Yes 281 146 54.8 (47.6-61.0) 1.36 (1.13-1.64) 0.001 1.15 (0.95-1.39) 0.16
Platelet count
≥100,000/μl 732 326 42.9 (38.7-46.8) 1.00 (referent) 1.00 (referent)
<100,000/μl 525 281 51.4 (46.4-56.0) 1.27 (1.08-1.49) 0.003 1.44 (1.22-1.70) <0.001
BCLC
0 181 56 28.9 (20.9-36.1) 1.00 (referent) 1.00 (referent)
A 588 264 40.8 (36.2-45.0) 1.49 (1.12-1.99) 0.007 1.41 (1.05-1.88) 0.021
B 427 234 55.6 (50.0-60.7) 2.35 (1.76-3.15) <0.001 2.11 (1.57-2.83) <0.001
C 47 41 96.3 (78.4-99.4) 16.41 (10.88-24.75) <0.001 13.6 (8.80-20.9) <0.001
D 14 12 91.1 (43.9-98.6) 11.16 (5.97-20.85) <0.001 13.0 (6.86-24.7) <0.001
Previous treatment
No 786 346 40.5 (36.5-44.2) 1.00 (referent) 1.00 (referent)
Yes 471 261 56.9 (51.5-61.7) 1.61 (1.37-1.89) <0.001 1.32 (1.12-1.57) 0.001
α-fetoprotein
<100 ng/ml 979 440 42.8 (39.1-46.1) 1.00 (referent) 1.00 (referent)
≥100 ng/ml 278 167 59.6 (52.7-65.4) 1.65 (1.38-1.98) <0.001 1.51 (1.26-1.82) <0.001
HR, hazard ratio; CI, conﬁdence interval; BMI, body mass index; IMF, intramuscular fat; HCV, hepatitis C virus; HBV, hepatitis B virus; BCLC, Barcelona Clinic Liver Cancer.
*Data of 45 patients were missing.
Data of 99 patients were missing.
Data of 35 patients were missing.
Research ArticleDiscussion
In this study, we comprehensively analyzed the impact of body
composition on survival in a large-scale cohort of patients in var-
ious stages of HCC and determined that sarcopenia, IMF deposi-
tion, and visceral adiposity rather than BMI were independent
risk factors for a poor prognosis. In addition, we found that the
proportion of patients who had two or three poor prognostic
body composition components was signiﬁcantly higher in under-
weight and obese patients than that in normal weight patients.
Thus, the high prevalence of poor prognostic body composition
factors in underweight and obese patients may be an explanation
for the U-shaped relationship between BMI and mortality in
patients with HCC.
We found that quantity (deﬁned by low SMI) and quality
(deﬁned by low MA) of muscle were indicators of a poor progno-
sis in patients with HCC. This is the ﬁrst report showing the neg-
ative effect of low MA on survival in patients with HCC. Low MA
indicates IMF deposition, which contributes to muscle weakness
independent of the age-associated loss in muscle mass [23].
Muscle weakness caused by sarcopenia and/or IMF deposition
reduces activities associated with daily living. In addition, sarco-
penia and IMF deposition are associated with insulin resistance
[29], vitamin D deﬁciency [30], and increased inﬂammatory cyto-
kine levels, such as interleukin-6 (IL-6) [31], all of which are asso-
ciated with progression of liver ﬁbrosis and HCC [32–34].
Therefore, the quantity and quality of skeletal muscle may be
linked to the prognosis of patients with HCC through various
mechanisms. Importantly, sarcopenia and IMF deposition were
more strongly associated with a poor prognosis than was older
age in our study, indicating that functional age rather than chro-
nological age is a critical factor for HCC patients.
Although several reports have revealed associations between
muscle depletion and survival in HCC patients of Western138 Journal of Hepatology 201countries [14] and Japan [35], the cut-off values associated with
poor survival and development of sarcopenia vary widely by eth-
nicity and/or region. Since no consensus value for CT-based sar-
copenia has been established in Asian populations, we
determined the cut-off values associated with poor survival in
the present study (36.2 cm2/m2 in males and 29.6 cm2/m2 in
females). Using these values, we found that the proportion of
patients with sarcopenia was 11.1%. These cut-off values and
prevalence levels were relatively lower than those in Western
countries. However, using the cut-off value deﬁned by an interna-
tional consensus as the appropriate value to use to identify can-
cer cachexia [36], 80.5% of patients had cachexia, but this cutoff
did not predict survival (data not shown). In contrast, the
cut-off values derived in a very recent study from Japan were
very similar to ours (36.0 cm2/m2 in males and 29.0 cm2/m2 in
females) [11]. Accordingly, the values we have calculated are
likely to be adequate, at least for Japanese patients. Our results
will be useful for establishing diagnostic criteria for Asians. Of
note, contrary to SMI, the MA thresholds were similar to those
of Western countries [10].
A higher VSR was associated with a poor prognosis in HCC
patients, whereas BMI, VATI, and SATI were not. This ﬁnding sug-
gests that the distribution of adipose tissue rather than the abso-
lute value is a major determinant for the prognosis of HCC
patients. Adipose tissue controls the function of other organs by
secreting adipokines. Visceral fat accumulation increases the lev-
els of pro-inﬂammatory adipokines such as tumor necrosis
factor-a, IL-6, and monocyte chemoattractant protein-1, and
decreases that of the anti-inﬂammatory adipokine adiponectin
[37]. In addition, excess visceral fat leads to impaired suppression
of FFA release in response to insulin [38]. As FFAs and adipokines
released from visceral fat ﬂow directly into the liver though the
portal vein, the liver can be inﬂuenced markedly by such changes.
In contrast, subcutaneous fat effectively stores excess lipids and5 vol. 63 j 131–140
BMI category
No. of 
prognostic
factor
N HR 95% Cl p value
Underweight
Normal weight
Obesity
0
1
2 or 3
25
83
78
0
1
2 or 3
0
1
2 or 3
97
468
135
36
238
97
Hazard ratio
0.5 1.0 2.0 5.0
1.00
1.81
3.44
0.93
1.66
2.40
1.56
2.05
2.09
(Ref.)
(0.84-3.89) 0.13
0.001
0.86
0.16
0.019
0.30
0.049
0.055(0.99-4.42)
(1.00-4.20)
(0.67-3.62)
(1.16-4.98)
(0.82-3.35)
(0.43-2.01)
(1.63-7.25)
 p <0.001
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Fig. 4. Impacts of prognostic body compositions on survival stratiﬁed by BMI
categories. (A) Underweight patients without any of the three negative
prognostic variables exhibited a long survival time, whereas those who were
underweight and had two or three prognostic factors had the shortest survival
time. (B) Patients with two or three prognostic body composition factors were
more prevalent among the underweight and obesity categories, which may lead
to a poor prognosis among underweight and obese patients, as shown in
Supplementary Fig. 1.
JOURNAL OF HEPATOLOGYprevents their leakage into other organs. Furthermore, Tran et al.
showed that transplanting subcutaneous fat into the visceral fat
cavity improves glucose metabolism in mice, suggesting that sub-
cutaneous fat cell itself can exert a metabolically advantageous
function [39]. Thus, subcutaneous fat-dominant obesity may be a
‘‘metabolically healthy’’ status. In fact, diabetes was more preva-
lent among patients exhibiting visceral adiposity in this study.
However, we could not address questions of causality in the pres-
ent work. Thus, further basic and clinical studies are required.
The strength of our study was its large sample size of patients
at different stages of HCC. However, some limitations are appar-
ent. First, because the study was retrospective, CT data were not
available for some patients, and this may have caused selection
bias. Second, the study was observational; therefore, we could
not infer causality between the body composition components
and mortality. Finally, our cohort may not be representative of
patients with HCC in general because of potential referral bias.
In conclusion, body composition rather than BMI is important
in terms of survival of HCC patients, independently of liver func-
tion reserve and cancer stage. Variations in the impact of BMI on
survival were explained in part by differences in body composi-
tion. We plan to conduct a prospective study investigating
whether interventions targeting body composition, such asJournal of Hepatology 201nutritional support, exercise therapy, and the use of drugs to pre-
vent muscle depletion, improve the survival of HCC patients.Financial support
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